JPS638111B2 - - Google Patents
Info
- Publication number
- JPS638111B2 JPS638111B2 JP53004764A JP476478A JPS638111B2 JP S638111 B2 JPS638111 B2 JP S638111B2 JP 53004764 A JP53004764 A JP 53004764A JP 476478 A JP476478 A JP 476478A JP S638111 B2 JPS638111 B2 JP S638111B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- quinuclidine
- carboxylic acid
- arrhythmia
- xylidide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 70
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- LIUAALCHBQSCCX-UHFFFAOYSA-N 1-azoniabicyclo[2.2.2]octane-2-carboxylate Chemical compound C1CN2C(C(=O)O)CC1CC2 LIUAALCHBQSCCX-UHFFFAOYSA-N 0.000 claims description 21
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 12
- PUIHXLMMFNAYNW-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octane-3-carboxylic acid Chemical compound C1CC2C(C(=O)O)CN1CC2 PUIHXLMMFNAYNW-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- UFFBMTHBGFGIHF-UHFFFAOYSA-N 2,6-dimethylaniline Chemical group CC1=CC=CC(C)=C1N UFFBMTHBGFGIHF-UHFFFAOYSA-N 0.000 claims description 10
- 150000001448 anilines Chemical class 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 description 26
- 230000006793 arrhythmia Effects 0.000 description 26
- 230000000694 effects Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- 230000003288 anthiarrhythmic effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 10
- 229960004194 lidocaine Drugs 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000010253 intravenous injection Methods 0.000 description 8
- 229940105631 nembutal Drugs 0.000 description 7
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 7
- 206010047302 ventricular tachycardia Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 5
- 244000166550 Strophanthus gratus Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 5
- 229960003343 ouabain Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 231100000189 neurotoxic Toxicity 0.000 description 4
- 230000002887 neurotoxic effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 3
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- JOIJZJVAIURHGA-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octane-2-carboxylic acid;hydrochloride Chemical compound Cl.C1CN2C(C(=O)O)CC1CC2 JOIJZJVAIURHGA-UHFFFAOYSA-N 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- KGPPDNUWZNWPSI-UHFFFAOYSA-N flurotyl Chemical compound FC(F)(F)COCC(F)(F)F KGPPDNUWZNWPSI-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- HCIRLKXASKPUHN-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-1-azabicyclo[2.2.2]octane-3-carboxamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1C(CC2)CCN2C1 HCIRLKXASKPUHN-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- COLOHWPRNRVWPI-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound [CH2]C(F)(F)F COLOHWPRNRVWPI-UHFFFAOYSA-N 0.000 description 1
- LXHNHXQYRPDFPN-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octane-3-carboxylic acid;hydrochloride Chemical compound Cl.C1CC2C(C(=O)O)CN1CC2 LXHNHXQYRPDFPN-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000021264 digitalis poisoning Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000792 effect on seizure Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 229950000929 flurotyl Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Description
æ¬çºæã¯æå¹ãªæäžæŽèå€ã§ããããšãç«èšŒã
ããååç©ã§ããããã¯ãªãžã³âïŒâã«ã«ãã³é ž
ã®ïŒã»ïŒâãã·ãªãžãåã³ãã®è£œå€çã«èš±å®¹ãã
åŸãå¡©ããŸãã¯æäžæŽèäœçšã®ãªããäŸãã°ãã
ã¯ãªãžã³âïŒâã«ã«ãã³é žãã·ãªãžãã®ãããªé¢
é£ååç©ã®è£œæ³ã«ä¿ãããæ¬çºæã®è£œæ³ã§ã¯ãã
ã¯ãªãžã³ã«ã«ãã³é žãç¡æ°Žã¯ãããã«ã åã³å¡©å
ãªããµãªã«äžã§ãžã¡ãã«ã¢ããªã³ãšåå¿ãããã
ãšã«ãã€ãŠåèšååç©ã調補ãããææã®ååç©
ã¯é«åéãé«çŽåºŠã§èª¿è£œãããã åŸæ¥äžæŽèã®æ²»çã«ãªãã«ã€ã³åã³ããã«é¡äŒŒ
ã®ååç©ã䜿çšãããå ç¶éšã®æ²»çæ段ãšããŠã
䜿çšãããŠããããçç©åŠçåæžæãçŽ75åéã«
ãããªãã®ã§æ¥æ»ãæããããªçå矀ã®äºé²ã«å©
çšããäºã¯äžå¯èœã§ããããŸããè žç®¡ããã®ãªã
ã«ã€ã³ã®åžåã¯äžå åã§ãããäœè¡å§ãç¥çµæ¯ãª
ã©ã®æ害ãªå¯äœçšãåããæ²»çææ°ïŒè¬ç©ã®è容
éãšæå¹éãšã®æ¯ïŒã¯äœããããã«ã代è¬ãè¿ é
ã§ãããããå åãªè¡æŒ¿æ¿åºŠãç¶æããããã«ã¯
éèå æç¶ç¹æ»Žæ³šå ¥æ³ã«ãã€ãŠãªãã«ã€ã³ãæäž
ããªããã°ãªããªãã åŸã€ãŠãæäžæŽèäœçšãæ¹åãã補å€ã®éçºã
ç®ãããŠçµ¶ããç 究ãæšé²ãããŠæ¥ãã ã¢ã¯ããã©ã²ããã»ã¢ã¹ãã©ïŒAktiebolaget
AstraïŒã«ä»äžããããã©ã³ã¹ç¹èš±ç¬¬1565045å·
ã¯åŒ ã§è¡šããããååç©çŸ€ãé瀺ããŠãããäœãR1
åã³R2ã¯æ°ŽçŽ ãããã²ã³ãŸãã¯äœçŽã¢ã«ãã«ã§
ããããã®ç¹èš±ã¯ãŸããããã¯ãªãžã³ã«ã«ãã³é ž
ããã®ã¡ãã«ãšã¹ãã«ã«å€æããåŸæ²åã¡ãã«ã
ã°ãã·ãŠã åã³é©åœãªã¢ããªã³ã®æ··åç©ã§åŠçã
ãããšãç¹åŸŽãšããäžèšååç©çŸ€ã®è£œæ³ãé瀺ã
ãŠãããäœããåçã¯äœããæ害ãªå¯çç©ã«ãã€
ãŠæ±æãããã äžèšãã©ã³ã¹ç¹èš±ã¯å ·äœçãªäŸãšããŠããã¯ãª
ãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãªãžããæ
ãããã®ååç©ãæäžæŽèäœçšåã³å±éšéº»é äœçš
ãæããããšãææããŠããããããæ¬çºæè ç
ã®è¿œè©Šã«ããããã®ååç©ã¯ç¥çµæ¯ã§ãããæçš
ãªæäžæŽèäœçšã¯å šããªãããšãå€æããã ããŒã«ãã ïŒDahlbomïŒåã³ãã«ããŒ
ïŒDolbyïŒã¯ãã¢ã¯ã¿ã»ãã¢ã«ãã»ã¹ãšãã«
ïŒActa Pharma.SuecicaïŒã第65å·ç¬¬277é ïŒ1969
幎çºè¡ïŒã«æ²èŒãããè«æã«æŒããŠãååç©ïŒ®â
ïŒããã¯ãªãžã³âïŒâã«ã«ããã«ïŒâïŒã»ïŒâãžã¡
ãã«ã¢ããªã³ãå«ãããã¯ãªãžã³âïŒâã«ã«ãã³
é žã®åçš®èªå°äœã«ã€ããŠå ±åããåçš®ã®è¬çåŠç
åã³åŸ®çç©åŠçäœçšã«ã€ããŠãããã®ååç©ãè©Š
éšããçµæã埮匱ãªå±éšéº»é äœçšä»¥å€ã«äœçã®è¬
çåŠçå¹æããªãããšãææããŠããã äžèšãã¢ã¯ã¿ã»ãã¢ã«ãã»ã¹ãšãã«ãã®è«æã«
ããã°ãããã¯ãªãžã³ã«ã«ãã³é žã®å¡©é žå¡©ãå¡©å
ããªãã«ã®ååšã«æŒããŠéæµäžã«äŸãã°ïŒã»ïŒâ
ãžã¡ãã«ã¢ããªã³ã®ãããªã¢ããªã³ãšåå¿ããã
ããšã«ãã€ãŠäžèšååç©ã調補ãããããããã
ã®åå¿ã¯åå¿ç©ãèããå€è²ãããçµæã¯äžæã§
ãããææã®çæç©ãæ±æããå«ç¡«ç©è³ªã圢æã
ãããã®è£œæ³ã«ãã€ãŠåŸãããäžå®å šã«ç²Ÿè£œãã
ãçæç©ã®åçã¯å€ãã®å Žåçè«å€ã®60ïŒ ãè¶ ã
ãããšãã§ããªãã ãã¢ã¯ã¿ã»ãã¢ã«ãã»ã¹ãšãã«ãã«èšèŒã®æ瀺
ã«ãæãããããã¯ãªãžã³âïŒâã«ã«ãã³é žã®
ïŒã»ïŒâãã·ãªãžãåã³è£œå€çã«èš±å®¹ããåŸãã
ã®å¡©ãäŸãã°å¡©é žå¡©ãæ害ãªå¯äœçšã䌎ãªãããš
ãªãé«åºŠã®æäžæŽèäœçšãåããããšãæ¬çºæã§
æããã«ãããããã©ã³ã¹ç¹èš±ç¬¬1566045å·ãé
瀺ããããã¯ãªãžã³âïŒâã«ã«ãã³é žïŒã»ïŒâã
ã·ãªãžããç¥çµæ¯æ§ã䌎ãªããæçšãªäžæŽèæ²»ç
å¹æãæ¬ ããšäºãäºå®ãèæ ®ããã°ããã¯é©ãã¹
ãããšã§ããã æ¬çºæã¯ããã¯ãªãžã³ã«ã«ãã³é žåã³ã¢ããªã³
èªå°äœããåŒ ã§è¡šããããã¢ããã補é ããæ¹æ³ãå³ã¡ãå¡©å
ãªããµãªã«ã®ååšã«æŒããŠç¡æ°Žã¯ãããã«ã äžã§
ããã¯ãªãžã³ã«ã«ãã³é žãé©åœãªã¢ããªã³èªå°äœ
ãšåå¿ãããããšã«ãã€ãŠäžèšåŒã§è¡šããããå
åç©ãåæããããšãç¹åŸŽãšãã補æ³ã«ä¿ããã
äœããäžèšåŒã«æŒããŠR1åã³R2ã¯æ°ŽçŽ ãããã²
ã³ãŸãã¯äœçŽã¢ã«ãã«ãè¡šããããã®è£œæ³ãå¿çš
ããã°çè«å€ã®90ïŒ ä»¥äžã®åçã§çŽç²ãªåœ¢ã®ææ
ååç©ãåŸãããšãã§ããã åŸã€ãŠæ¬çºæã®ç®çã¯ããã¯ãªãžã³ã«ã«ãã³é ž
ã®ã¢ããªã³èªå°äœãç¹ã«äžæŽèæ²»çå¹æãæãã
ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãª
ãžãã®è£œæ³ãæäŸããããšã«ããã æ¬çºæã®ãã®ä»ã®ç®çåã³å©ç¹ã¯ä»¥äžã®èª¬æå
ã³ç¹èš±è«æ±ã®ç¯å²ã®èšèŒã«ããæããã§ãããã äžè¿°ã®åã³ãã®ä»ã®ç®çã«ç §ãããŠãæ¬çºæã¯
å¡©åãªããµãªã«ã®ååšã«æŒããŠç¡æ°Žã¯ãããã«ã
äžã§ããã¯ãªãžã³ã«ã«ãã³é žïŒãŸãã¯ãã®é žæ·»å
å¡©ãäŸãã°å¡©é žå¡©ïŒãéæµäžã«é©åœãªã¢ããªã³ãš
åå¿ãããããšã«ãã€ãŠããã¯ãªãžã³âïŒâã«ã«
ãã³é žã®ïŒã»ïŒâãã·ãªãžãåã³ããã«é¢é£ãã
ååç©ãåæãã補æ³ã察象ãšããã æ¢ã«ææããããã«ãããã¯ãªãžã³âïŒâã«ã«
ãã³é žã®ïŒã»ïŒâãã·ãªãžãã¯ç¥çµæ¯ã§ãããæ
çšãªæäžæŽèäœçšãæ¬ ããããã®ç°æ§äœãå³ã¡åŒ ã§è¡šããããããã¯ãªãžã³âïŒâã«ã«ãã³é žã®
ïŒã»ïŒâãã·ãªãžãã¯å¯äœçšãã»ãšãã©äŒŽãªãã
ã«ããããæäžæŽèäœçšãåãããšäºãäºå®ãæ¬
çºæã§æããã«ãªã€ããäžæŽèæ²»çå¹æãåŸãã«
ã¯ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·
ãªãžãã®ççé©åæ§å¡©ãªããããªãå¡©ã§ã䜿çšã§
ãããã奜ãŸããã¯é©éã®å¡©é žå¡©ã䜿çšãããå¡©
é žå¡©ã¯å¯æº¶æ§ãé«ãå ¥æãæãããã§ããã æ¬çºæã«ããè¬å€ã®æå¹ãªæäžæŽèäœçšãç«èšŒ
ãããããããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»
ïŒâãã·ãªãžãå¡©é žå¡©ïŒäŸ¿å®äžä»¥äžã«ãååç©
ããšåŒç§°ããïŒãå ¬ç¥ã®æäžæŽèå€ãšæ¯èŒãã
ãšå ±ã«ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâ
ãã·ãªãžãå¡©é žå¡©ïŒäŸ¿å®äžä»¥äžã«ãååç©ããš
åŒç§°ããïŒãšãæ¯èŒããã äžèšã®å®æœäŸã¯æ¬çºæ補æ³ã®ç解ã容æã«ãã
ããã®ãã®ã§ãããæ¬çºæããããã®å®æœäŸã«å¶
éãããã®ã§ã¯ãªãã å®æœäŸ ïŒ ãã®å®æœäŸã¯æ¬çºæã®è£œæ³ãå©çšããããã¯ãª
ãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãªãžãå¡©é ž
å¡©ïŒååç©ïŒã®è£œé ã«é¢ããå®æœäŸã§ããã ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®å¡©é žå¡©2.5ïœ
ïŒ0.013ã¢ã«ïŒãç¡æ°Žã®äžã€ã¢ã«ã³ãŒã«ãå«ãŸãªã
ã¯ãããã«ã ïŒ150c.c.ïŒã«æº¶ããããå¡©åãªããµ
ãªã«ïŒ10mlïŒãæ·»å ãã倧æ°äžã®æ°Žåããé®æã
ããã¬ã©ã¹è£ 眮å ã§ïŒæéã«äºããã®æ··åç©ãé
æµãããåŸã溶åªãèžçºãããŠä¹Ÿç¥ããã 次ãã§ç¡æ°Žã®äžã€ã¢ã«ã³ãŒã«ãå«ãŸãªãã¯ãã
ãã«ã 100mlã«ïŒã»ïŒâãžã¡ãã«ã¢ããªã³ïŒïœ
ïŒ0.025ã¢ã«ïŒã溶ããã溶液ã§æ··åç©ãåŠçãã
ïŒæéã«äºã€ãŠéæµããããèžæºïŒ80âã®ãªã€ã«
ãã¹ïŒã«ããæ®çºæ§æº¶åªãæ®ããé€å»ããæ®çå
ã3Nã®äœæž©å¡©é žæ°Žæº¶æ¶²25mlã§åŠçããã éæé žæº¶æ¶²éšåãå°éã®äžå¯æº¶æ§æ®çåããã
ã«ã³ãããïŒïŒ æ°Žé žåãããªãŠã 氎溶液ã§PHã
4.5ã«èª¿æŽãããšãŒãã«ïŒ25mlïŒã§ïŒåºŠæœåºãã
ãšãŒãã«æœåºç©ãå»æ£ãããPHãïŒãŸã§äžããæ°Ž
溶液ãåã³ãšãŒãã«ïŒ25mlïŒã§æœåºããããšãŒã
ã«æœåºç©ã«ã¯ååãããïŒã»ïŒâãžã¡ãã«ã¢ããª
ã³ãå«ãŸããŠããã氎溶液ã匷ã¢ã«ã«ãªæ§ã«ãã
ãšãæ²æŸ±ç©ãšããŠææã®ååç©ãåŸãããããã
ãã¯ãããã«ã ïŒ50mlïŒã§æœåºããæžå§äžã§ã¯ã
ããã«ã 溶液ãèžçºä¹Ÿç¥ãããæ®çåãïŒïŒ å¡©å
æ°ŽçŽ ã¡ã¿ããŒã«æº¶æ¶²200mlã«æº¶ãããåŸããã溶
液ãåã³èžçºä¹Ÿç¥ããããã¡ã¿ããŒã«åã³ãšãŒã
ã«ïŒïŒïŒïŒïŒã®æ··åç©ããæ®çåãåçµæ¶ãã
ããåéïŒå¡©é žå¡©ïŒååç©ïŒèç¹234â236âïŒ
ïŒïœãæ¿çž®ã«ãã€ãŠæ¯æ¶²ããè¿œå éïŒ0.5ïœïŒã
ååããããçŽç²ååç©ã®ç·åéã¯çè«å€ã®91ïŒ
ã§ãã€ãã ããããæ¬çºæã®å¡©åãªããµãªã«ã®ä»£ãã«å¡©å
ããªãã«ãå©çšããŠäžèšè£œæ³ãå®æœããçµæãå
å¿æ··åç©ã«èããå€è²ãèµ·ãããçµæäžæã®ç¡«é»
å«æç©è³ªã圢æããããããææã®çæç©ãæ±æ
ãããã®çµæãäžéšç²Ÿè£œãããçæç©ã®åçãç
è«å€ã®60ïŒ ãŸãã¯ãã以äžã«ãšã©ãŸã€ãã å®æœäŸ ïŒ ãã®å®æœäŸã¯æ¬çºæã®è£œæ³ãå©çšããããã¯ãª
ãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãªãžãå¡©é ž
å¡©ïŒååç©ïŒã®åæã«é¢ããå®æœäŸã§ããã ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®å¡©é žå¡©1.5ïœ
ïŒ0.0078ã¢ã«ïŒãç¡æ°Žã®äžã€ã¢ã«ã³ãŒã«ãå«ãŸãª
ãã¯ãããã«ã 100mlã«æº¶ããããå¡©åãªããµãª
ã«ïŒïŒmlïŒãæ·»å ãã倧æ°äžã®æ°Žåããé®æãã
ãã¬ã©ã¹è£ 眮å ã§éææ··åç©ãïŒæéã«äºã€ãŠé
æµããã溶åªãèžçºä¹Ÿç¥ããããç¡æ°Žã®äžã€ã¢ã«
ã³ãŒã«ãå«ãŸãªãã¯ãããã«ã 50mlã«ïŒã»ïŒâãž
ã¡ãã«ã¢ããªã³1.5ïœïŒ0.0125ã¢ã«ïŒã溶ããã
溶液ã§æ··åç©ãåŠçããïŒæéã«äºã€ãŠéæµãã
ãã 80âã®ãªã€ã«ãã¹ã§èžæºããããšã«ããæ®çºæ§
溶åªãé€å»ããæ®çåã3Nã®äœæž©å¡©é žæ°Žæº¶æ¶²ã«
溶ãããå°éã®äžå¯æº¶æ®çåããäžæŸã¿æº¶æ¶²ãã
ã«ã³ããããïŒïŒ æ°Žé žåãããªãŠã 氎溶液ãæ·»å
ããŠéæ溶液ã®PHã5.5ã«èª¿æŽããŠããããšãŒã
ã«25mlã§æœåºããããšãŒãã«æœåºç©ã«ã¯ååãã
ãïŒã»ïŒâãžã¡ãã«ã¢ããªã³ãå«ãŸããŠãããæ°Ž
é žåãããªãŠã ã§æ°Žçžã匷ã¢ã«ã«ãªæ§ã«ããŠãã
ã¯ãããã«ã 100mlã§æœåºãããã¯ãããã«ã æœ
åºæº¶æ¶²ãèžçºä¹Ÿç¥ãããæ®çåã掻åä¿æ°ïŒãã¯
ãããã°ã©ãã€ãŒçŽã®äžæ§ã¢ã«ããããæãçŽåŸ
ïŒcmãé·ã50cmã®å¡ã®é éšã«ç©å±€ããããçŽïŒ
ã®ãã³ãŒã³ã§æº¶é¢åŠçããããšã«ããäžçŽç©ãæŽ
æ»ããã次ã«ååç©ãã¯ãããã«ã ïŒ500c.c.ïŒ
ã§æº¶é¢åŠçãããååããã¯ãããã«ã 溶液ãèž
çºä¹Ÿç¥ãããæ®çåãïŒïŒ å¡©åæ°ŽçŽ ã¡ã¿ããŒã«æº¶
液ïŒ100c.c.ïŒã«æº¶ããããã®æº¶æ¶²ãèžçºãããã¡
ã¿ããŒã«åã³ãšãŒãã«ïŒïŒïŒïŒïŒã®æ··åç©ããæ®
çåãåçµæ¶ãããŠå¡©é žå¡©ïŒååç©ïŒãåŸãã
åéã¯ïŒïœïŒçè«å€ã®50ïŒ ïŒãèç¹ã¯216âã§ãã€
ãã 以äžã«è¿°ã¹ãååç©ã®è£œæ³ã¯ããã¯ãªãžã³â
ïŒâã«ã«ãã³é žããã®ã¡ãã«ãšã¹ãã«ã«å€æãã
ãããæ²åã¡ãã«ãã°ãã·ãŠã åã³ïŒã»ïŒâãžã¡
ãã«ã¢ããªã³ã®æ··åç©ã§åŠçãããã©ã³ã¹ç¹èš±ç¬¬
1566045å·ã«èšèŒã®è£œæ³ãããã¯ããã«ãŸãã€ãŠ
ãããå³ã¡ãæ¬çºæã®è£œæ³ã¯é«ãåçãšçŽåºŠãé
æãããããã«åããŠãæ¬çºæã®è£œæ³ã«æŒããŠäœ¿
çšãããå¡©åãªããµãªã«ã®ä»£ãã«å¡©åããªãã«ã
代çšããŠååç©ã調補ããããšããã°ãããã¯
ãªãžã³âïŒâã«ã«ãã³é žã«èããå解ãèµ·ããã
çµæäžæã®ã¿ãŒã«ç¶å«ç¡«ç©è³ªã圢æãããããã
枬å®ã§ããã»ã©ã®åéã¯åŸãããªãã ååç©ã®æäžæŽèäœçšããã®ä»ã®è¬çç¹æ§å
ã³å¯äœçšãå ¬ç¥ã®æäžæŽèå€ãšæ¯èŒããäžæ¹ãå
åç©ãšãæ¯èŒããçµæã以äžã«è©³è¿°ããã äœéã20â25ïœã®ICRã¢ã«ããããŠã¹ïŒãïŒã«
è¬å€ã®0.5ïŒ æº¶æ¶²ãè ¹è å 泚å°ããŠååç©ã®æ¯
æ§ã枬å®ãããïŒå¹ãã€ã®ã°ã«ãŒãã«åããŠæè¬
ããã被éšäœåæã«ãã€ãŠåŸãããLD50ã¯60±
ïŒmgïŒKgã§ãã€ãã ååç©ã¯ä»ã®äžæ¢äœçšæ§è¬å€ãšã®éã«çžäºäœ
çšã瀺ããªãã€ãããããã¯äžæ¢ç¥çµç³»ã«å¯Ÿãã
掻æ§ãååç©ã«æ¬ ããŠããããšã®èšŒæ ã§ãããš
èãããããã¡ãã©ãŸãŒã«ãæäžãã30ã60åã³
90ååã«ååç©ãè ¹è å 泚å°ããçµæãã¡ãã©
ãŸãŒã«æäžã§èªçºãããçæ£ïŒã¡ãã©ãŸãŒã«100
mgïŒKgïŒã«å¯ŸããŠååç©ã¯åœ±é¿ã瀺ããªãã€
ãããªããœãã¬ã¢ãªã³ïŒoxotremorineïŒæäžã®
30ååã«ååç©ãè ¹è å 泚å°ããçµæããªããœ
ãã¬ã¢ãªã³ã§èªçºãããæ¯é¡«ïŒãªããœãã¬ã¢ãªã³
20ÎŒïœïŒKgè ¹è å 泚å°ïŒã«å¯ŸããŠåœ±é¿ã瀺ããªã
ã€ããååç©ãè ¹è å 泚å°ããŠ30ååŸã«ã€ã³ã
ã¯ãã³ãIndoklonïŒãããµãã«ãªããžãšãã«ãš
ãŒãã«ïŒCF3CH2ââCH2CF3ïŒã®åæšåãã
åžå ¥ããããããŸãã¯30ãã«ãã®é»æ°ã·ãšãã¯ã
äžããçµæãã€ã³ãã¯ãã³ã«ããçºäœãŸãã¯é»æ°
ã·ãšãã¯ã«ããçºäœã«å¯ŸããŠååç©ã圱é¿ããª
ãããšãå€æããã æèã®ããå¥åº·ãªç¬ã«15â30ç§ã«äºã€ãŠïŒmgïŒ
Kgã®ååç©ãéè泚å°ããçµæãå¯Ÿç §ãšæ¯èŒã
ãŠå§¿å¢ãè¡åãŸãã¯æ 調ã«èããå€åã¯èŠãããª
ãã€ãã æèã®ããå¥åº·ãªç¬ã«ååç©ãéè泚å°ããŠ
æ£åžžãªå¿èã«å¯Ÿãã圱é¿ãæ€æ»ããçºã«ã泚å°åŸ
ïŒæéã«äºã€ãŠå¿é»å³ã®ãªãŒããã¢ãã¿ãŒã
ããåèšïŒé ã«å¯ŸããïŒmgïŒKgãïŒåã ãæäžã
ãå Žåãšã30â60åã«äºã€ãŠïŒmgïŒKgãïŒmgïŒKg
åã³ïŒmgïŒKgã«åããŠèšïŒmgïŒKgã环å ããå Žå
ãšã芳å¯ããçµæãå¿é»å³ã«å€åã¯èªããããªã
ã€ãã å¿èå ã«äžéæ§ã®é«ãååç©ã®æ¿åºŠãåŸãã
ããïŒä»¶ã ãïŒmgïŒKgãïŒåºŠã«äžã€éãã«æäžã
ããQRSæ³¢ã®å¹ ãåºãã€ããããã®ã»ãã«æ¯æ§
å¹æã瀺ã城åã¯èªããããªãã€ããå¿é»å³ã¯15
å以å ã«åžžæ ã«åŸ©åž°ããã ãã³ãã¿ãŒã«éº»é ããç¬ïŒãã³ãã¿ãŒã«25mgïŒ
KgïŒã«å¯Ÿãã30åã«äºã€ãŠïŒmgïŒKgãïŒmgïŒKgå
ã³ïŒmgïŒKgã«åããŠååç©ãèšïŒmgïŒKg环å ç
ã«éè泚å°ãããšãããå¿é»å³ã«å€åã¯èªããã
ãªãã€ãã ãã³ãã¿ãŒã«éº»é ããç«ã§ã¯ç¬ãšç°ãªãåå¿ã
èªããããã34åã«äºã€ãŠå°ããã€åèšïŒmgïŒKg
ã®ååç©ãæäžããçµæãQRSæ³¢ãå·Šæ¹ãžç§»
åãããïŒmgïŒKgåã³10.5mgïŒKgããããã环å
æäžããäŸã§ã¯QRSæ³¢ã®å¹ ãåºãã€ãããæŽæ§
æåïŒsinusrhythmïŒã¯ç¶æããããäŸãã°16.5
mgïŒKgïŒçŽ¯å ïŒãšäºãããã«æäžéãå¢ãããäŸ
ã§ã¯ç¬¬ïŒçŽAVãããã¯ãçŸãããã波ãåºã
ãªãããšããæãããªããã«å¿æ¿äŒéé床ã¯äœäž
ããããã®æ®µéã§æè¬ãäžæããã°40ååŸã«æ¿ã
ãæ¯æ§å¹æã¯æ¶ããå¿èãæ£åžžãªæŽæ§æåã«åŸ©åž°
ãããšæããããããã«å€§éã®ãäŸãã°7.5mgïŒ
Kgã®ååç©ãæäžãããšïŒçŽ¯èšæäžéïŒ24mgïŒ
KgïŒãé«åºŠã®AVãããã¯ãçŸãããç¶ããŠå¿è
ãåæ¢ããã ãŠã¢ãã€ã³ã«ãã€ãŠèªçºãããäžæŽèã«ã€ããŠ
å®æœããè©Šéšã«ã€ããŠä»¥äžã«èª¬æããã ãåã³âã®ç«ïŒ1.8â3.4KgïŒããã³ãã¿ãŒã«
ïŒ40mgïŒKgè ¹è å 泚å°ïŒã§éº»é ãããåŒåžè·¯ã確
ä¿ããããæ°ç®¡ã«ã«ããŠãŒã«ãæ¿å ¥ããããã³ã
ã¿ãŒã«æäžããä»ã®è¬å€ã®æäžãŸã§ã«åŒåžå°é£ã
芳å¯ãããå Žåã«éã人工åŒåžãæ¡çšããïŒ10件
ã®ãã¡ïŒä»¶ïŒãè¡å§æž¬å®åã³è¬å€æäžã®ããã«å€§
è ¿åèåã³å€§è ¿éèã«ããããã«ããŠãŒã«ãæ¿å ¥
ãããã°ã©ã¹ïŒåããªã°ãªãïŒGrass
Model7polygraphïŒã«ããå¿é»å³ã®ãªãŒãã
çµå§ã¢ãã¿ãŒãããæäžè¬å€æº¶æ¶²ã¯ãã¹ãŠé£å¡©æ°Ž
äžã®æº¶æ¶²ãšãããïŒã€ã®æ æ§ã§ãŠã¢ãã€ã³ãæäž
ããããšã«ããäžæŽèãèªçºãããå³ã¡ã30åæ¯
ã«å°éãã€æ³šå°ãããããããã¯é£ç¶çã«æ³šå ¥ã
ããå°ããšãïŒæéã«äºãåèš75â80ÎŒïœïŒKgã
æäžããåŸå¿å®€æ§é »èïŒVTïŒãèµ·ããã®ãæ®é
ã§ããã äžæŽèèªçºåŸã30ç§ã«äºãïŒmgïŒ0.2mlïŒKgé
ã®ååç©ãéè泚å°ãããå€ãã®å Žåããã®åŠ
眮ãããïŒåºŠç¹°è¿ãããããïŒæé以å ã«äžæŽè
ãåçºããå Žåãæäžéã0.5mgïŒKgã«æžãããã
æ¯èŒã®ãããåãèŠé ã§ãªãã«ã€ã³ãæäžããã éçš®ç¬ã䜿çšããä»ã®å®éšã§ã¯ãã³ãã¿ãŒã«
ïŒ25mgïŒKgïŒãéè泚å°ããŠéº»é ããŠããã30å
ééã§40ÎŒïœïŒKgã20ÎŒïœïŒKgåã³10ÎŒïœïŒKgãšäº
ãããã«æ¬¡ç¬¬ã«æžéããªãããŠã¢ãã€ã³ãæäžã
ãŠäžæŽèãèªçºããã次ãã§äžèšã®ããã«ååç©
ã«ããæ²»çãå®æœããã ãŠã¢ãã€ã³ã环å çã«70â90ÎŒïœïŒKgç«ã«æäž
ããŠå®åžžçãªäžæŽèç¶æ ãšããŠãã10ååŸã«ïŒå
ã®æ²»çæè¬ãšããŠååç©ãïŒmgïŒKgæäžããçµ
æãåäžæ¡ä»¶äžã§ãªãã«ã€ã³ãæäžããå Žåãã
ãã¯ããã«é·æéã«äºã€ãŠå¿é»å³ã®èããæ¹åã
æç¶ãããååç©ã§æ²»çããç«ã«é¢ããçµæã
è¡šïŒã«ããªãã«ã€ã³æ²»çã®çµæãè¡šïŒã«ãããã
æ²ç€ºããã ç¬ã§ã¯ååç©ã®ïŒåæäžïŒïŒmgïŒKgïŒã§å¿å®€
æ§é »èïŒVTïŒãæ£åžžãªæŽæ§æåã«åŸ©æ§ããã45
ååŸã«äžæŽèãåçºããå Žåã«ã¯æåã®æäžéã®
ïŒïŒïŒã«çžåœããååç©ãè¿œå æäžããããšã§æ£
åžžãªæŽæ§æåã«åŸ©æ§ãããããšãã§ããïŒè¡šïŒïŒã
ããååç©ã§ããããã¯ãªãžã³âïŒâã«ã«ãã³é ž
ã®ïŒã»ïŒâãã·ãªãžãåã³ãã®è£œå€çã«èš±å®¹ãã
åŸãå¡©ããŸãã¯æäžæŽèäœçšã®ãªããäŸãã°ãã
ã¯ãªãžã³âïŒâã«ã«ãã³é žãã·ãªãžãã®ãããªé¢
é£ååç©ã®è£œæ³ã«ä¿ãããæ¬çºæã®è£œæ³ã§ã¯ãã
ã¯ãªãžã³ã«ã«ãã³é žãç¡æ°Žã¯ãããã«ã åã³å¡©å
ãªããµãªã«äžã§ãžã¡ãã«ã¢ããªã³ãšåå¿ãããã
ãšã«ãã€ãŠåèšååç©ã調補ãããææã®ååç©
ã¯é«åéãé«çŽåºŠã§èª¿è£œãããã åŸæ¥äžæŽèã®æ²»çã«ãªãã«ã€ã³åã³ããã«é¡äŒŒ
ã®ååç©ã䜿çšãããå ç¶éšã®æ²»çæ段ãšããŠã
䜿çšãããŠããããçç©åŠçåæžæãçŽ75åéã«
ãããªãã®ã§æ¥æ»ãæããããªçå矀ã®äºé²ã«å©
çšããäºã¯äžå¯èœã§ããããŸããè žç®¡ããã®ãªã
ã«ã€ã³ã®åžåã¯äžå åã§ãããäœè¡å§ãç¥çµæ¯ãª
ã©ã®æ害ãªå¯äœçšãåããæ²»çææ°ïŒè¬ç©ã®è容
éãšæå¹éãšã®æ¯ïŒã¯äœããããã«ã代è¬ãè¿ é
ã§ãããããå åãªè¡æŒ¿æ¿åºŠãç¶æããããã«ã¯
éèå æç¶ç¹æ»Žæ³šå ¥æ³ã«ãã€ãŠãªãã«ã€ã³ãæäž
ããªããã°ãªããªãã åŸã€ãŠãæäžæŽèäœçšãæ¹åãã補å€ã®éçºã
ç®ãããŠçµ¶ããç 究ãæšé²ãããŠæ¥ãã ã¢ã¯ããã©ã²ããã»ã¢ã¹ãã©ïŒAktiebolaget
AstraïŒã«ä»äžããããã©ã³ã¹ç¹èš±ç¬¬1565045å·
ã¯åŒ ã§è¡šããããååç©çŸ€ãé瀺ããŠãããäœãR1
åã³R2ã¯æ°ŽçŽ ãããã²ã³ãŸãã¯äœçŽã¢ã«ãã«ã§
ããããã®ç¹èš±ã¯ãŸããããã¯ãªãžã³ã«ã«ãã³é ž
ããã®ã¡ãã«ãšã¹ãã«ã«å€æããåŸæ²åã¡ãã«ã
ã°ãã·ãŠã åã³é©åœãªã¢ããªã³ã®æ··åç©ã§åŠçã
ãããšãç¹åŸŽãšããäžèšååç©çŸ€ã®è£œæ³ãé瀺ã
ãŠãããäœããåçã¯äœããæ害ãªå¯çç©ã«ãã€
ãŠæ±æãããã äžèšãã©ã³ã¹ç¹èš±ã¯å ·äœçãªäŸãšããŠããã¯ãª
ãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãªãžããæ
ãããã®ååç©ãæäžæŽèäœçšåã³å±éšéº»é äœçš
ãæããããšãææããŠããããããæ¬çºæè ç
ã®è¿œè©Šã«ããããã®ååç©ã¯ç¥çµæ¯ã§ãããæçš
ãªæäžæŽèäœçšã¯å šããªãããšãå€æããã ããŒã«ãã ïŒDahlbomïŒåã³ãã«ããŒ
ïŒDolbyïŒã¯ãã¢ã¯ã¿ã»ãã¢ã«ãã»ã¹ãšãã«
ïŒActa Pharma.SuecicaïŒã第65å·ç¬¬277é ïŒ1969
幎çºè¡ïŒã«æ²èŒãããè«æã«æŒããŠãååç©ïŒ®â
ïŒããã¯ãªãžã³âïŒâã«ã«ããã«ïŒâïŒã»ïŒâãžã¡
ãã«ã¢ããªã³ãå«ãããã¯ãªãžã³âïŒâã«ã«ãã³
é žã®åçš®èªå°äœã«ã€ããŠå ±åããåçš®ã®è¬çåŠç
åã³åŸ®çç©åŠçäœçšã«ã€ããŠãããã®ååç©ãè©Š
éšããçµæã埮匱ãªå±éšéº»é äœçšä»¥å€ã«äœçã®è¬
çåŠçå¹æããªãããšãææããŠããã äžèšãã¢ã¯ã¿ã»ãã¢ã«ãã»ã¹ãšãã«ãã®è«æã«
ããã°ãããã¯ãªãžã³ã«ã«ãã³é žã®å¡©é žå¡©ãå¡©å
ããªãã«ã®ååšã«æŒããŠéæµäžã«äŸãã°ïŒã»ïŒâ
ãžã¡ãã«ã¢ããªã³ã®ãããªã¢ããªã³ãšåå¿ããã
ããšã«ãã€ãŠäžèšååç©ã調補ãããããããã
ã®åå¿ã¯åå¿ç©ãèããå€è²ãããçµæã¯äžæã§
ãããææã®çæç©ãæ±æããå«ç¡«ç©è³ªã圢æã
ãããã®è£œæ³ã«ãã€ãŠåŸãããäžå®å šã«ç²Ÿè£œãã
ãçæç©ã®åçã¯å€ãã®å Žåçè«å€ã®60ïŒ ãè¶ ã
ãããšãã§ããªãã ãã¢ã¯ã¿ã»ãã¢ã«ãã»ã¹ãšãã«ãã«èšèŒã®æ瀺
ã«ãæãããããã¯ãªãžã³âïŒâã«ã«ãã³é žã®
ïŒã»ïŒâãã·ãªãžãåã³è£œå€çã«èš±å®¹ããåŸãã
ã®å¡©ãäŸãã°å¡©é žå¡©ãæ害ãªå¯äœçšã䌎ãªãããš
ãªãé«åºŠã®æäžæŽèäœçšãåããããšãæ¬çºæã§
æããã«ãããããã©ã³ã¹ç¹èš±ç¬¬1566045å·ãé
瀺ããããã¯ãªãžã³âïŒâã«ã«ãã³é žïŒã»ïŒâã
ã·ãªãžããç¥çµæ¯æ§ã䌎ãªããæçšãªäžæŽèæ²»ç
å¹æãæ¬ ããšäºãäºå®ãèæ ®ããã°ããã¯é©ãã¹
ãããšã§ããã æ¬çºæã¯ããã¯ãªãžã³ã«ã«ãã³é žåã³ã¢ããªã³
èªå°äœããåŒ ã§è¡šããããã¢ããã補é ããæ¹æ³ãå³ã¡ãå¡©å
ãªããµãªã«ã®ååšã«æŒããŠç¡æ°Žã¯ãããã«ã äžã§
ããã¯ãªãžã³ã«ã«ãã³é žãé©åœãªã¢ããªã³èªå°äœ
ãšåå¿ãããããšã«ãã€ãŠäžèšåŒã§è¡šããããå
åç©ãåæããããšãç¹åŸŽãšãã補æ³ã«ä¿ããã
äœããäžèšåŒã«æŒããŠR1åã³R2ã¯æ°ŽçŽ ãããã²
ã³ãŸãã¯äœçŽã¢ã«ãã«ãè¡šããããã®è£œæ³ãå¿çš
ããã°çè«å€ã®90ïŒ ä»¥äžã®åçã§çŽç²ãªåœ¢ã®ææ
ååç©ãåŸãããšãã§ããã åŸã€ãŠæ¬çºæã®ç®çã¯ããã¯ãªãžã³ã«ã«ãã³é ž
ã®ã¢ããªã³èªå°äœãç¹ã«äžæŽèæ²»çå¹æãæãã
ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãª
ãžãã®è£œæ³ãæäŸããããšã«ããã æ¬çºæã®ãã®ä»ã®ç®çåã³å©ç¹ã¯ä»¥äžã®èª¬æå
ã³ç¹èš±è«æ±ã®ç¯å²ã®èšèŒã«ããæããã§ãããã äžè¿°ã®åã³ãã®ä»ã®ç®çã«ç §ãããŠãæ¬çºæã¯
å¡©åãªããµãªã«ã®ååšã«æŒããŠç¡æ°Žã¯ãããã«ã
äžã§ããã¯ãªãžã³ã«ã«ãã³é žïŒãŸãã¯ãã®é žæ·»å
å¡©ãäŸãã°å¡©é žå¡©ïŒãéæµäžã«é©åœãªã¢ããªã³ãš
åå¿ãããããšã«ãã€ãŠããã¯ãªãžã³âïŒâã«ã«
ãã³é žã®ïŒã»ïŒâãã·ãªãžãåã³ããã«é¢é£ãã
ååç©ãåæãã補æ³ã察象ãšããã æ¢ã«ææããããã«ãããã¯ãªãžã³âïŒâã«ã«
ãã³é žã®ïŒã»ïŒâãã·ãªãžãã¯ç¥çµæ¯ã§ãããæ
çšãªæäžæŽèäœçšãæ¬ ããããã®ç°æ§äœãå³ã¡åŒ ã§è¡šããããããã¯ãªãžã³âïŒâã«ã«ãã³é žã®
ïŒã»ïŒâãã·ãªãžãã¯å¯äœçšãã»ãšãã©äŒŽãªãã
ã«ããããæäžæŽèäœçšãåãããšäºãäºå®ãæ¬
çºæã§æããã«ãªã€ããäžæŽèæ²»çå¹æãåŸãã«
ã¯ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·
ãªãžãã®ççé©åæ§å¡©ãªããããªãå¡©ã§ã䜿çšã§
ãããã奜ãŸããã¯é©éã®å¡©é žå¡©ã䜿çšãããå¡©
é žå¡©ã¯å¯æº¶æ§ãé«ãå ¥æãæãããã§ããã æ¬çºæã«ããè¬å€ã®æå¹ãªæäžæŽèäœçšãç«èšŒ
ãããããããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»
ïŒâãã·ãªãžãå¡©é žå¡©ïŒäŸ¿å®äžä»¥äžã«ãååç©
ããšåŒç§°ããïŒãå ¬ç¥ã®æäžæŽèå€ãšæ¯èŒãã
ãšå ±ã«ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâ
ãã·ãªãžãå¡©é žå¡©ïŒäŸ¿å®äžä»¥äžã«ãååç©ããš
åŒç§°ããïŒãšãæ¯èŒããã äžèšã®å®æœäŸã¯æ¬çºæ補æ³ã®ç解ã容æã«ãã
ããã®ãã®ã§ãããæ¬çºæããããã®å®æœäŸã«å¶
éãããã®ã§ã¯ãªãã å®æœäŸ ïŒ ãã®å®æœäŸã¯æ¬çºæã®è£œæ³ãå©çšããããã¯ãª
ãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãªãžãå¡©é ž
å¡©ïŒååç©ïŒã®è£œé ã«é¢ããå®æœäŸã§ããã ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®å¡©é žå¡©2.5ïœ
ïŒ0.013ã¢ã«ïŒãç¡æ°Žã®äžã€ã¢ã«ã³ãŒã«ãå«ãŸãªã
ã¯ãããã«ã ïŒ150c.c.ïŒã«æº¶ããããå¡©åãªããµ
ãªã«ïŒ10mlïŒãæ·»å ãã倧æ°äžã®æ°Žåããé®æã
ããã¬ã©ã¹è£ 眮å ã§ïŒæéã«äºããã®æ··åç©ãé
æµãããåŸã溶åªãèžçºãããŠä¹Ÿç¥ããã 次ãã§ç¡æ°Žã®äžã€ã¢ã«ã³ãŒã«ãå«ãŸãªãã¯ãã
ãã«ã 100mlã«ïŒã»ïŒâãžã¡ãã«ã¢ããªã³ïŒïœ
ïŒ0.025ã¢ã«ïŒã溶ããã溶液ã§æ··åç©ãåŠçãã
ïŒæéã«äºã€ãŠéæµããããèžæºïŒ80âã®ãªã€ã«
ãã¹ïŒã«ããæ®çºæ§æº¶åªãæ®ããé€å»ããæ®çå
ã3Nã®äœæž©å¡©é žæ°Žæº¶æ¶²25mlã§åŠçããã éæé žæº¶æ¶²éšåãå°éã®äžå¯æº¶æ§æ®çåããã
ã«ã³ãããïŒïŒ æ°Žé žåãããªãŠã 氎溶液ã§PHã
4.5ã«èª¿æŽãããšãŒãã«ïŒ25mlïŒã§ïŒåºŠæœåºãã
ãšãŒãã«æœåºç©ãå»æ£ãããPHãïŒãŸã§äžããæ°Ž
溶液ãåã³ãšãŒãã«ïŒ25mlïŒã§æœåºããããšãŒã
ã«æœåºç©ã«ã¯ååãããïŒã»ïŒâãžã¡ãã«ã¢ããª
ã³ãå«ãŸããŠããã氎溶液ã匷ã¢ã«ã«ãªæ§ã«ãã
ãšãæ²æŸ±ç©ãšããŠææã®ååç©ãåŸãããããã
ãã¯ãããã«ã ïŒ50mlïŒã§æœåºããæžå§äžã§ã¯ã
ããã«ã 溶液ãèžçºä¹Ÿç¥ãããæ®çåãïŒïŒ å¡©å
æ°ŽçŽ ã¡ã¿ããŒã«æº¶æ¶²200mlã«æº¶ãããåŸããã溶
液ãåã³èžçºä¹Ÿç¥ããããã¡ã¿ããŒã«åã³ãšãŒã
ã«ïŒïŒïŒïŒïŒã®æ··åç©ããæ®çåãåçµæ¶ãã
ããåéïŒå¡©é žå¡©ïŒååç©ïŒèç¹234â236âïŒ
ïŒïœãæ¿çž®ã«ãã€ãŠæ¯æ¶²ããè¿œå éïŒ0.5ïœïŒã
ååããããçŽç²ååç©ã®ç·åéã¯çè«å€ã®91ïŒ
ã§ãã€ãã ããããæ¬çºæã®å¡©åãªããµãªã«ã®ä»£ãã«å¡©å
ããªãã«ãå©çšããŠäžèšè£œæ³ãå®æœããçµæãå
å¿æ··åç©ã«èããå€è²ãèµ·ãããçµæäžæã®ç¡«é»
å«æç©è³ªã圢æããããããææã®çæç©ãæ±æ
ãããã®çµæãäžéšç²Ÿè£œãããçæç©ã®åçãç
è«å€ã®60ïŒ ãŸãã¯ãã以äžã«ãšã©ãŸã€ãã å®æœäŸ ïŒ ãã®å®æœäŸã¯æ¬çºæã®è£œæ³ãå©çšããããã¯ãª
ãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãªãžãå¡©é ž
å¡©ïŒååç©ïŒã®åæã«é¢ããå®æœäŸã§ããã ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®å¡©é žå¡©1.5ïœ
ïŒ0.0078ã¢ã«ïŒãç¡æ°Žã®äžã€ã¢ã«ã³ãŒã«ãå«ãŸãª
ãã¯ãããã«ã 100mlã«æº¶ããããå¡©åãªããµãª
ã«ïŒïŒmlïŒãæ·»å ãã倧æ°äžã®æ°Žåããé®æãã
ãã¬ã©ã¹è£ 眮å ã§éææ··åç©ãïŒæéã«äºã€ãŠé
æµããã溶åªãèžçºä¹Ÿç¥ããããç¡æ°Žã®äžã€ã¢ã«
ã³ãŒã«ãå«ãŸãªãã¯ãããã«ã 50mlã«ïŒã»ïŒâãž
ã¡ãã«ã¢ããªã³1.5ïœïŒ0.0125ã¢ã«ïŒã溶ããã
溶液ã§æ··åç©ãåŠçããïŒæéã«äºã€ãŠéæµãã
ãã 80âã®ãªã€ã«ãã¹ã§èžæºããããšã«ããæ®çºæ§
溶åªãé€å»ããæ®çåã3Nã®äœæž©å¡©é žæ°Žæº¶æ¶²ã«
溶ãããå°éã®äžå¯æº¶æ®çåããäžæŸã¿æº¶æ¶²ãã
ã«ã³ããããïŒïŒ æ°Žé žåãããªãŠã 氎溶液ãæ·»å
ããŠéæ溶液ã®PHã5.5ã«èª¿æŽããŠããããšãŒã
ã«25mlã§æœåºããããšãŒãã«æœåºç©ã«ã¯ååãã
ãïŒã»ïŒâãžã¡ãã«ã¢ããªã³ãå«ãŸããŠãããæ°Ž
é žåãããªãŠã ã§æ°Žçžã匷ã¢ã«ã«ãªæ§ã«ããŠãã
ã¯ãããã«ã 100mlã§æœåºãããã¯ãããã«ã æœ
åºæº¶æ¶²ãèžçºä¹Ÿç¥ãããæ®çåã掻åä¿æ°ïŒãã¯
ãããã°ã©ãã€ãŒçŽã®äžæ§ã¢ã«ããããæãçŽåŸ
ïŒcmãé·ã50cmã®å¡ã®é éšã«ç©å±€ããããçŽïŒ
ã®ãã³ãŒã³ã§æº¶é¢åŠçããããšã«ããäžçŽç©ãæŽ
æ»ããã次ã«ååç©ãã¯ãããã«ã ïŒ500c.c.ïŒ
ã§æº¶é¢åŠçãããååããã¯ãããã«ã 溶液ãèž
çºä¹Ÿç¥ãããæ®çåãïŒïŒ å¡©åæ°ŽçŽ ã¡ã¿ããŒã«æº¶
液ïŒ100c.c.ïŒã«æº¶ããããã®æº¶æ¶²ãèžçºãããã¡
ã¿ããŒã«åã³ãšãŒãã«ïŒïŒïŒïŒïŒã®æ··åç©ããæ®
çåãåçµæ¶ãããŠå¡©é žå¡©ïŒååç©ïŒãåŸãã
åéã¯ïŒïœïŒçè«å€ã®50ïŒ ïŒãèç¹ã¯216âã§ãã€
ãã 以äžã«è¿°ã¹ãååç©ã®è£œæ³ã¯ããã¯ãªãžã³â
ïŒâã«ã«ãã³é žããã®ã¡ãã«ãšã¹ãã«ã«å€æãã
ãããæ²åã¡ãã«ãã°ãã·ãŠã åã³ïŒã»ïŒâãžã¡
ãã«ã¢ããªã³ã®æ··åç©ã§åŠçãããã©ã³ã¹ç¹èš±ç¬¬
1566045å·ã«èšèŒã®è£œæ³ãããã¯ããã«ãŸãã€ãŠ
ãããå³ã¡ãæ¬çºæã®è£œæ³ã¯é«ãåçãšçŽåºŠãé
æãããããã«åããŠãæ¬çºæã®è£œæ³ã«æŒããŠäœ¿
çšãããå¡©åãªããµãªã«ã®ä»£ãã«å¡©åããªãã«ã
代çšããŠååç©ã調補ããããšããã°ãããã¯
ãªãžã³âïŒâã«ã«ãã³é žã«èããå解ãèµ·ããã
çµæäžæã®ã¿ãŒã«ç¶å«ç¡«ç©è³ªã圢æãããããã
枬å®ã§ããã»ã©ã®åéã¯åŸãããªãã ååç©ã®æäžæŽèäœçšããã®ä»ã®è¬çç¹æ§å
ã³å¯äœçšãå ¬ç¥ã®æäžæŽèå€ãšæ¯èŒããäžæ¹ãå
åç©ãšãæ¯èŒããçµæã以äžã«è©³è¿°ããã äœéã20â25ïœã®ICRã¢ã«ããããŠã¹ïŒãïŒã«
è¬å€ã®0.5ïŒ æº¶æ¶²ãè ¹è å 泚å°ããŠååç©ã®æ¯
æ§ã枬å®ãããïŒå¹ãã€ã®ã°ã«ãŒãã«åããŠæè¬
ããã被éšäœåæã«ãã€ãŠåŸãããLD50ã¯60±
ïŒmgïŒKgã§ãã€ãã ååç©ã¯ä»ã®äžæ¢äœçšæ§è¬å€ãšã®éã«çžäºäœ
çšã瀺ããªãã€ãããããã¯äžæ¢ç¥çµç³»ã«å¯Ÿãã
掻æ§ãååç©ã«æ¬ ããŠããããšã®èšŒæ ã§ãããš
èãããããã¡ãã©ãŸãŒã«ãæäžãã30ã60åã³
90ååã«ååç©ãè ¹è å 泚å°ããçµæãã¡ãã©
ãŸãŒã«æäžã§èªçºãããçæ£ïŒã¡ãã©ãŸãŒã«100
mgïŒKgïŒã«å¯ŸããŠååç©ã¯åœ±é¿ã瀺ããªãã€
ãããªããœãã¬ã¢ãªã³ïŒoxotremorineïŒæäžã®
30ååã«ååç©ãè ¹è å 泚å°ããçµæããªããœ
ãã¬ã¢ãªã³ã§èªçºãããæ¯é¡«ïŒãªããœãã¬ã¢ãªã³
20ÎŒïœïŒKgè ¹è å 泚å°ïŒã«å¯ŸããŠåœ±é¿ã瀺ããªã
ã€ããååç©ãè ¹è å 泚å°ããŠ30ååŸã«ã€ã³ã
ã¯ãã³ãIndoklonïŒãããµãã«ãªããžãšãã«ãš
ãŒãã«ïŒCF3CH2ââCH2CF3ïŒã®åæšåãã
åžå ¥ããããããŸãã¯30ãã«ãã®é»æ°ã·ãšãã¯ã
äžããçµæãã€ã³ãã¯ãã³ã«ããçºäœãŸãã¯é»æ°
ã·ãšãã¯ã«ããçºäœã«å¯ŸããŠååç©ã圱é¿ããª
ãããšãå€æããã æèã®ããå¥åº·ãªç¬ã«15â30ç§ã«äºã€ãŠïŒmgïŒ
Kgã®ååç©ãéè泚å°ããçµæãå¯Ÿç §ãšæ¯èŒã
ãŠå§¿å¢ãè¡åãŸãã¯æ 調ã«èããå€åã¯èŠãããª
ãã€ãã æèã®ããå¥åº·ãªç¬ã«ååç©ãéè泚å°ããŠ
æ£åžžãªå¿èã«å¯Ÿãã圱é¿ãæ€æ»ããçºã«ã泚å°åŸ
ïŒæéã«äºã€ãŠå¿é»å³ã®ãªãŒããã¢ãã¿ãŒã
ããåèšïŒé ã«å¯ŸããïŒmgïŒKgãïŒåã ãæäžã
ãå Žåãšã30â60åã«äºã€ãŠïŒmgïŒKgãïŒmgïŒKg
åã³ïŒmgïŒKgã«åããŠèšïŒmgïŒKgã环å ããå Žå
ãšã芳å¯ããçµæãå¿é»å³ã«å€åã¯èªããããªã
ã€ãã å¿èå ã«äžéæ§ã®é«ãååç©ã®æ¿åºŠãåŸãã
ããïŒä»¶ã ãïŒmgïŒKgãïŒåºŠã«äžã€éãã«æäžã
ããQRSæ³¢ã®å¹ ãåºãã€ããããã®ã»ãã«æ¯æ§
å¹æã瀺ã城åã¯èªããããªãã€ããå¿é»å³ã¯15
å以å ã«åžžæ ã«åŸ©åž°ããã ãã³ãã¿ãŒã«éº»é ããç¬ïŒãã³ãã¿ãŒã«25mgïŒ
KgïŒã«å¯Ÿãã30åã«äºã€ãŠïŒmgïŒKgãïŒmgïŒKgå
ã³ïŒmgïŒKgã«åããŠååç©ãèšïŒmgïŒKg环å ç
ã«éè泚å°ãããšãããå¿é»å³ã«å€åã¯èªããã
ãªãã€ãã ãã³ãã¿ãŒã«éº»é ããç«ã§ã¯ç¬ãšç°ãªãåå¿ã
èªããããã34åã«äºã€ãŠå°ããã€åèšïŒmgïŒKg
ã®ååç©ãæäžããçµæãQRSæ³¢ãå·Šæ¹ãžç§»
åãããïŒmgïŒKgåã³10.5mgïŒKgããããã环å
æäžããäŸã§ã¯QRSæ³¢ã®å¹ ãåºãã€ãããæŽæ§
æåïŒsinusrhythmïŒã¯ç¶æããããäŸãã°16.5
mgïŒKgïŒçŽ¯å ïŒãšäºãããã«æäžéãå¢ãããäŸ
ã§ã¯ç¬¬ïŒçŽAVãããã¯ãçŸãããã波ãåºã
ãªãããšããæãããªããã«å¿æ¿äŒéé床ã¯äœäž
ããããã®æ®µéã§æè¬ãäžæããã°40ååŸã«æ¿ã
ãæ¯æ§å¹æã¯æ¶ããå¿èãæ£åžžãªæŽæ§æåã«åŸ©åž°
ãããšæããããããã«å€§éã®ãäŸãã°7.5mgïŒ
Kgã®ååç©ãæäžãããšïŒçŽ¯èšæäžéïŒ24mgïŒ
KgïŒãé«åºŠã®AVãããã¯ãçŸãããç¶ããŠå¿è
ãåæ¢ããã ãŠã¢ãã€ã³ã«ãã€ãŠèªçºãããäžæŽèã«ã€ããŠ
å®æœããè©Šéšã«ã€ããŠä»¥äžã«èª¬æããã ãåã³âã®ç«ïŒ1.8â3.4KgïŒããã³ãã¿ãŒã«
ïŒ40mgïŒKgè ¹è å 泚å°ïŒã§éº»é ãããåŒåžè·¯ã確
ä¿ããããæ°ç®¡ã«ã«ããŠãŒã«ãæ¿å ¥ããããã³ã
ã¿ãŒã«æäžããä»ã®è¬å€ã®æäžãŸã§ã«åŒåžå°é£ã
芳å¯ãããå Žåã«éã人工åŒåžãæ¡çšããïŒ10件
ã®ãã¡ïŒä»¶ïŒãè¡å§æž¬å®åã³è¬å€æäžã®ããã«å€§
è ¿åèåã³å€§è ¿éèã«ããããã«ããŠãŒã«ãæ¿å ¥
ãããã°ã©ã¹ïŒåããªã°ãªãïŒGrass
Model7polygraphïŒã«ããå¿é»å³ã®ãªãŒãã
çµå§ã¢ãã¿ãŒãããæäžè¬å€æº¶æ¶²ã¯ãã¹ãŠé£å¡©æ°Ž
äžã®æº¶æ¶²ãšãããïŒã€ã®æ æ§ã§ãŠã¢ãã€ã³ãæäž
ããããšã«ããäžæŽèãèªçºãããå³ã¡ã30åæ¯
ã«å°éãã€æ³šå°ãããããããã¯é£ç¶çã«æ³šå ¥ã
ããå°ããšãïŒæéã«äºãåèš75â80ÎŒïœïŒKgã
æäžããåŸå¿å®€æ§é »èïŒVTïŒãèµ·ããã®ãæ®é
ã§ããã äžæŽèèªçºåŸã30ç§ã«äºãïŒmgïŒ0.2mlïŒKgé
ã®ååç©ãéè泚å°ãããå€ãã®å Žåããã®åŠ
眮ãããïŒåºŠç¹°è¿ãããããïŒæé以å ã«äžæŽè
ãåçºããå Žåãæäžéã0.5mgïŒKgã«æžãããã
æ¯èŒã®ãããåãèŠé ã§ãªãã«ã€ã³ãæäžããã éçš®ç¬ã䜿çšããä»ã®å®éšã§ã¯ãã³ãã¿ãŒã«
ïŒ25mgïŒKgïŒãéè泚å°ããŠéº»é ããŠããã30å
ééã§40ÎŒïœïŒKgã20ÎŒïœïŒKgåã³10ÎŒïœïŒKgãšäº
ãããã«æ¬¡ç¬¬ã«æžéããªãããŠã¢ãã€ã³ãæäžã
ãŠäžæŽèãèªçºããã次ãã§äžèšã®ããã«ååç©
ã«ããæ²»çãå®æœããã ãŠã¢ãã€ã³ã环å çã«70â90ÎŒïœïŒKgç«ã«æäž
ããŠå®åžžçãªäžæŽèç¶æ ãšããŠãã10ååŸã«ïŒå
ã®æ²»çæè¬ãšããŠååç©ãïŒmgïŒKgæäžããçµ
æãåäžæ¡ä»¶äžã§ãªãã«ã€ã³ãæäžããå Žåãã
ãã¯ããã«é·æéã«äºã€ãŠå¿é»å³ã®èããæ¹åã
æç¶ãããååç©ã§æ²»çããç«ã«é¢ããçµæã
è¡šïŒã«ããªãã«ã€ã³æ²»çã®çµæãè¡šïŒã«ãããã
æ²ç€ºããã ç¬ã§ã¯ååç©ã®ïŒåæäžïŒïŒmgïŒKgïŒã§å¿å®€
æ§é »èïŒVTïŒãæ£åžžãªæŽæ§æåã«åŸ©æ§ããã45
ååŸã«äžæŽèãåçºããå Žåã«ã¯æåã®æäžéã®
ïŒïŒïŒã«çžåœããååç©ãè¿œå æäžããããšã§æ£
åžžãªæŽæ§æåã«åŸ©æ§ãããããšãã§ããïŒè¡šïŒïŒã
ãè¡šã
ãè¡šã
ãè¡šã
ç¥åã¯è¡šïŒãšåãã
ãïŒ11åã³12ã§ã¯4mgïŒKgã13ã§ã¯1.6mgïŒKgã®é
ã§1åã ããªãã«ã€ã³HClãéè泚å°ããã
ããïŒäžæŽèãåçºããã
ãïŒ11åã³12ã§ã¯4mgïŒKgã13ã§ã¯1.6mgïŒKgã®é
ã§1åã ããªãã«ã€ã³HClãéè泚å°ããã
ããïŒäžæŽèãåçºããã
ãè¡šã
ç¥åã¯è¡šïŒãšåãã
ãïŒãã®æéåŸã«äžæŽèãåçºããã0.25mgïŒKg
ã®EOâ122ã1åéè泚å°ããããšã«ãã€ãŠæå¶
ãããã
æèã®ããç¬ã«æŒããéå¡æ§äžæŽèã«å¯ŸããŠå
åç©ãéçµè žæäžãããã®å¹æãè©äŸ¡ãããé
å¡å¹æãåŸããããïŒé ã®ç¬ã«æŒããŠå·Šåäžè¡å
ç¶åèãçµçŽ®ãããäžæŽèãçŸããããïŒãïŒæ¥
åŸã«èªç¶å埩ããã ååç©ãçµçŽ®åŸ24æé以å ã«ïŒåºŠã48æé以
å ã«ïŒåºŠæäžããã24æé以å ã«ïŒåïŒmgïŒKgã
éè泚å°ãããšããã20åéã«äºãäžæã®ãªãå®
å šãªæŽæ§æåãå埩ãã以åŸïŒâïŒæéã«äºã€ãŠ
SRãVTåã³VPBãæ··ããåã€ãŠçŸããããç¶
ã24æé以å ã®æè¬ã§ã¯ãã€ãšå°éã§ãäŸãã°
1.5mgïŒKgã§åãææãåŸããåŸã€ãŠæ²»ççè¡äž
æ¿åºŠã¯5ÎŒïœïŒc.c.åã³2.5ÎŒïœïŒc.c.ã§ãã€ãã åãç¬ã«ãªãã«ã€ã³ïŒmgïŒKgãéè泚å°ããã
å šãå¹æããªããããããã¯å¹æã極ããŠçæé
ããæç¶ããªãã€ãããªãã«ã€ã³ã®æäžã¯ååç©
æäžã®ïŒæéåãŸãã¯ïŒæéåŸãšãããããã
ã ãã®ééã眮ãã°ååç©ãšå¹æã环å ããªã
ãšã®ä»®å®ã«åºã¥ãã æèã®ããç¬ã«æŒããŠäžèšã®åŠãéå¡åŠçœ®ãæœ
ããŠèªçºããäžæŽèã«å¯Ÿããååç©ã®çµå£æäž
ã«ããå¹æãè©äŸ¡ããè©Šéšããå®æœããã äžè¿°ã®ããã«å·Šåäžè¡å ç¶åèãçµçŽ®ããŠäžæŽ
èãèªçºããåŸã15â20mgïŒKgã®ååç©ãïŒâ
ïŒåã®ãŒã©ãã³ã»ã«ãã»ã«ã«åããŠçµå£æäžãã
ãã®éã埮ç²åãåžéå€ãŸãã¯ãã€ãªã¢ãšã®æ··å
ã®ãããªäºååŠçãè¡ããªãã€ãããããã®äŸã§
ãæ£åžžãªæŽæ§æåãå埩ããå®å šãªå¹æã瀺ãã
ããçç¶ã®éãã«å¿ããŠæè¬åŸ11â60åã®é 延ã
䌎ãªã€ãã éå¡ã«ããäžæŽèçç¶ãåããæèã®ããç¬ã«
ã€ããŠååç©ã®è¬å¹ãã©ã¡ãŒã¿ãè©äŸ¡ãããïŒ
åã®æ²»çæäžéãéè泚å°ããåŸãéèè¡ãµã³ã
ã«ãäžå®ã®æéééã§æ¡åããããã«ãããªã³ã
æ·»å ããã¬ã¹ã¯ãããã°ã©ãã€ã«ããååç©å«
æåãåæ枬å®ããããã®åæã§äžèšã®ããŒã¿ã
åŸãã çç©åŠçåæžæïŒt1/2ïŒ ïŒãïŒæé ååžt1/2ïŒt1/2for distributionïŒ ïŒåé ååžå®¹ç©ïŒvolume of distributionïŒ
0.2ïŒKgïŒäœéïŒ æå¹è¡äžæ¿åºŠ 2.5â5ÎŒïœïŒml çµå£æäžãããååç©ã®çç©åŠçå¹åããæ
èã®ããå¥åº·ãªç¬ã«7.5mgïŒKgãæäžããçµæã§
è©äŸ¡ãããå°ãåèš7.5mgïŒKgã¯ïŒåã®ãŒã©ã
ã³ã»ã«ãã»ã«ã«åããåœåããæ»ãèœãšãããã
ãŒã¯è¡äžæ¿åºŠã¯æ¶ååŸïŒæéåŸã«çŸããã1.5â
2ÎŒïœïŒmlçšåºŠã§ãã€ããæ¶ååŸïŒæé以å ã«æ¶
åãããè¬å€ã®çŽ30ïŒ ãåžåãããããã®ããšã¯
åžåã»ææ³è€åååïŒcombined absorptionâ
elimination kineticsïŒã®AUCïŒæ²ç·äžæ¹åïŒã
枬å®ããããšã§è£ä»ããããšãã§ããã麻é ãæœ
ãããŠããªãäžæŽèã®ç¬ã§ã¯è¬å€ã®çç©åŠçå¹å
ã¯åçšåºŠãšèããããã 次ã«ååç©ã®äž»ãªæ§è³ªããªãã«ã€ã³ãšå¯Ÿæ¯ã
ãªããäžæ¬ããŠç€ºãã
ãïŒãã®æéåŸã«äžæŽèãåçºããã0.25mgïŒKg
ã®EOâ122ã1åéè泚å°ããããšã«ãã€ãŠæå¶
ãããã
æèã®ããç¬ã«æŒããéå¡æ§äžæŽèã«å¯ŸããŠå
åç©ãéçµè žæäžãããã®å¹æãè©äŸ¡ãããé
å¡å¹æãåŸããããïŒé ã®ç¬ã«æŒããŠå·Šåäžè¡å
ç¶åèãçµçŽ®ãããäžæŽèãçŸããããïŒãïŒæ¥
åŸã«èªç¶å埩ããã ååç©ãçµçŽ®åŸ24æé以å ã«ïŒåºŠã48æé以
å ã«ïŒåºŠæäžããã24æé以å ã«ïŒåïŒmgïŒKgã
éè泚å°ãããšããã20åéã«äºãäžæã®ãªãå®
å šãªæŽæ§æåãå埩ãã以åŸïŒâïŒæéã«äºã€ãŠ
SRãVTåã³VPBãæ··ããåã€ãŠçŸããããç¶
ã24æé以å ã®æè¬ã§ã¯ãã€ãšå°éã§ãäŸãã°
1.5mgïŒKgã§åãææãåŸããåŸã€ãŠæ²»ççè¡äž
æ¿åºŠã¯5ÎŒïœïŒc.c.åã³2.5ÎŒïœïŒc.c.ã§ãã€ãã åãç¬ã«ãªãã«ã€ã³ïŒmgïŒKgãéè泚å°ããã
å šãå¹æããªããããããã¯å¹æã極ããŠçæé
ããæç¶ããªãã€ãããªãã«ã€ã³ã®æäžã¯ååç©
æäžã®ïŒæéåãŸãã¯ïŒæéåŸãšãããããã
ã ãã®ééã眮ãã°ååç©ãšå¹æã环å ããªã
ãšã®ä»®å®ã«åºã¥ãã æèã®ããç¬ã«æŒããŠäžèšã®åŠãéå¡åŠçœ®ãæœ
ããŠèªçºããäžæŽèã«å¯Ÿããååç©ã®çµå£æäž
ã«ããå¹æãè©äŸ¡ããè©Šéšããå®æœããã äžè¿°ã®ããã«å·Šåäžè¡å ç¶åèãçµçŽ®ããŠäžæŽ
èãèªçºããåŸã15â20mgïŒKgã®ååç©ãïŒâ
ïŒåã®ãŒã©ãã³ã»ã«ãã»ã«ã«åããŠçµå£æäžãã
ãã®éã埮ç²åãåžéå€ãŸãã¯ãã€ãªã¢ãšã®æ··å
ã®ãããªäºååŠçãè¡ããªãã€ãããããã®äŸã§
ãæ£åžžãªæŽæ§æåãå埩ããå®å šãªå¹æã瀺ãã
ããçç¶ã®éãã«å¿ããŠæè¬åŸ11â60åã®é 延ã
䌎ãªã€ãã éå¡ã«ããäžæŽèçç¶ãåããæèã®ããç¬ã«
ã€ããŠååç©ã®è¬å¹ãã©ã¡ãŒã¿ãè©äŸ¡ãããïŒ
åã®æ²»çæäžéãéè泚å°ããåŸãéèè¡ãµã³ã
ã«ãäžå®ã®æéééã§æ¡åããããã«ãããªã³ã
æ·»å ããã¬ã¹ã¯ãããã°ã©ãã€ã«ããååç©å«
æåãåæ枬å®ããããã®åæã§äžèšã®ããŒã¿ã
åŸãã çç©åŠçåæžæïŒt1/2ïŒ ïŒãïŒæé ååžt1/2ïŒt1/2for distributionïŒ ïŒåé ååžå®¹ç©ïŒvolume of distributionïŒ
0.2ïŒKgïŒäœéïŒ æå¹è¡äžæ¿åºŠ 2.5â5ÎŒïœïŒml çµå£æäžãããååç©ã®çç©åŠçå¹åããæ
èã®ããå¥åº·ãªç¬ã«7.5mgïŒKgãæäžããçµæã§
è©äŸ¡ãããå°ãåèš7.5mgïŒKgã¯ïŒåã®ãŒã©ã
ã³ã»ã«ãã»ã«ã«åããåœåããæ»ãèœãšãããã
ãŒã¯è¡äžæ¿åºŠã¯æ¶ååŸïŒæéåŸã«çŸããã1.5â
2ÎŒïœïŒmlçšåºŠã§ãã€ããæ¶ååŸïŒæé以å ã«æ¶
åãããè¬å€ã®çŽ30ïŒ ãåžåãããããã®ããšã¯
åžåã»ææ³è€åååïŒcombined absorptionâ
elimination kineticsïŒã®AUCïŒæ²ç·äžæ¹åïŒã
枬å®ããããšã§è£ä»ããããšãã§ããã麻é ãæœ
ãããŠããªãäžæŽèã®ç¬ã§ã¯è¬å€ã®çç©åŠçå¹å
ã¯åçšåºŠãšèããããã 次ã«ååç©ã®äž»ãªæ§è³ªããªãã«ã€ã³ãšå¯Ÿæ¯ã
ãªããäžæ¬ããŠç€ºãã
ãè¡šã
ãè¡šã
以äžã®è©Šéšçµæããæãããªããã«ãæ¬çºæã®
ååç©ã¯ãªãã«ã€ã³ã®æäžæŽèäœçšãå ·ããã
ãã§ãªãããã®ä»ã«ãå€ãã®è¬ççé·æãå ·ããŠ
ãããå³ã¡ãçç©åŠçåæžæãé·ãããé£ç¶æ³šå ¥
ã®åœ¢ã§æè¬ããå¿ èŠããªãïŒçµå£æäžåŸã®çç©åŠ
çå¹åãé«ãããå埩泚å°ã®å¿ èŠããªãïŒäœè¡å§
ãäžæ¢ç¥çµç³»åºæ¿ã®ãããªå¯äœçšããªãããŸãå
åç©ã¯èèã«ãã€ãŠèããå€æ§ããããšããª
ããåŸã€ãŠãæ¬çºæã§ã¯äž»å€ãšããŠã®ååç©ãš
ãã®è¬ççã«æå¹ãªé žæ·»å å¡©ãïŒåã ããŸãã¯å
埩ããŠéè泚å°ããããšã«ããæ¥æ§å¿çæ¢å¡ã«ç¶
ãäžæŽèãæ²»çããããšãã§ããæ£è ãæ¬æ Œçãª
æ²»çæœèšãžç§»ãåãŸãã¯ãã®éäžã«ç·æ¥çšãšããŠ
å©çšããããšãã§ãããžã®ã¿ãªã¹äžæ¯ã«èµ·å ãã
äžæŽèã®æ²»çã«å©çšã§ããç¶ç¶æ²»ççšãšããŠçµå£
æäžæ¹åŒã§å©çšããããšãã§ããã æ¢ã«ææããéããäžèšã®äœçšå¹æãéæã§ã
ãã®ã¯ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâ
ãã·ãªãžãåã³ãã®ççé©åæ§ã®é žæ·»å å¡©ã ãã§
ããããã®ç°æ§äœã§ããããã¯ãªãžã³âïŒâã«ã«
ãã³é žã®ïŒã»ïŒâãã·ãªãžãã¯ç¥çµæ¯ãæããã
ãã§ãªããæå¹ãªäžæŽèæ²»çå¹æã«æ¬ ããããã®
ããšã¯ååç©ãå³ã¡ããã©ã³ã¹ç¹èš±ç¬¬1566045
å·ã®è£œæ³ã§ãæ¬çºæã®è£œæ³ã§ã調補ãããããã¯
ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãªãžãå¡©
é žå¡©ã«é¢ããè©Šéšã«ãã€ãŠç«èšŒããããååç©
ãã¢ã«ããããŠã¹ã«è ¹è å æäžããçµæãäžèšã®
çç¶ãçŸããããæ äž é äœ çš å¹ æ 20â30mgïŒKg è奮ã移æéåãå¢å€§ 40â60mgïŒKg ç¥çµäžæ¯ãéå倱調ãéšåéº»çº 100mgïŒKg èŽæ»éãæ»å ã¯åŒåžå°é£ãšèŠãã
ãã è¬å€ã«ããèªçºããäžæŽèã«å¯Ÿããååç©ã®äœ
çšå¹æ ããããããã³ãã¿ãŒã«ã§éº»é ããŠãã2.7Kg
ã®ç«ã«ïŒæéã«äºãåèš70ÎŒïœïŒKgã®ãŠã¢ãã€ã³
ããã€ããæ³šå ¥ããããšã«ãã€ãŠäžæŽèãçºçã
ããããã®æ®µéã§å¿é»å³ã¯äž»ãšããŠå¿å®€æ§æ©ææ
åïŒæå€åçž®ïŒåã³å¿å®€é »èã«ããäžæŽèã®æã
ããªå åã瀺ãããååç©ã1.1mgïŒKgã®å²å
ã§éè泚å°ãããšããã现åãèµ·ãããæ»ã«è³ã€
ãã å ç¶åèéå¡ã«ããèªçºããäžæŽèã«å¯Ÿããåå
ç©ã®äœçšå¹æ 000çªçµ¹ç³žã§å·Šåäžè¡å ç¶åèãçµçŽ®ããããš
ã«ããäœé15Kgã®ç¬ã«äžæŽèãçºçããããæè¡
ã®24æéåŸãäžæŽèãäž»ãšããŠå¿å®€æ§é »èã®æã
ããªå åãå¿é»å³ã«çŸããããïŒmgïŒKgã®å²åã§
ååç©ãéè泚å°ããããå¿é»å³ã«çæéå ã
ã«æ¹åã®å åãçŸãããã«éããªãã€ãããã®å
é¢ãç°åžžãªè奮ãéŠã暪ã«æ¯ããªã©ã®ç¥çµäžæ¯ç
ç¶ãã¯ã€ãã芳å¯ãããã 以äžã®çµæã«ç §ãããŠååç©ãæäžæŽèå€ãš
ããŠäœ¿çšã§ããªãããšã¯æçœã§ããã 以äžæ¬çºæã®è£œæ³ãç¹ã«ååç©åã³ã®èª¿è£œ
ã«é¢é£ããŠèª¬æããããäžè¬çã«ã¯åŒ ã§è¡šããããããã¯ãªãžã³ã«ã«ãã³é žãç¡æ°Žã¯ã
ããã«ã äžã§å¡©åãªããµãªã«ã®ååšã«æŒããŠåŒ ã§è¡šããããã¢ããªã³ãšåå¿ãããããšã«ãã察
å¿ã®ããã¯ãªãžã³ã«ã«ãã³é žãã·ãªãžããçæã
ãããããååããããšãç¹åŸŽãšããäžèšååç©
ãåã³ããã«é¡äŒŒã®ååç©ã®è£œæ³ã§ããããš
ã¯äºããŸã§ããªããå°äžèšåŒäžã®R1åã³R2ã¯å
ã«è¿°ã¹ãã®ãšåæ§ã®å 容ãè¡šãããã®ãšããã
ååç©ã¯ãªãã«ã€ã³ã®æäžæŽèäœçšãå ·ããã
ãã§ãªãããã®ä»ã«ãå€ãã®è¬ççé·æãå ·ããŠ
ãããå³ã¡ãçç©åŠçåæžæãé·ãããé£ç¶æ³šå ¥
ã®åœ¢ã§æè¬ããå¿ èŠããªãïŒçµå£æäžåŸã®çç©åŠ
çå¹åãé«ãããå埩泚å°ã®å¿ èŠããªãïŒäœè¡å§
ãäžæ¢ç¥çµç³»åºæ¿ã®ãããªå¯äœçšããªãããŸãå
åç©ã¯èèã«ãã€ãŠèããå€æ§ããããšããª
ããåŸã€ãŠãæ¬çºæã§ã¯äž»å€ãšããŠã®ååç©ãš
ãã®è¬ççã«æå¹ãªé žæ·»å å¡©ãïŒåã ããŸãã¯å
埩ããŠéè泚å°ããããšã«ããæ¥æ§å¿çæ¢å¡ã«ç¶
ãäžæŽèãæ²»çããããšãã§ããæ£è ãæ¬æ Œçãª
æ²»çæœèšãžç§»ãåãŸãã¯ãã®éäžã«ç·æ¥çšãšããŠ
å©çšããããšãã§ãããžã®ã¿ãªã¹äžæ¯ã«èµ·å ãã
äžæŽèã®æ²»çã«å©çšã§ããç¶ç¶æ²»ççšãšããŠçµå£
æäžæ¹åŒã§å©çšããããšãã§ããã æ¢ã«ææããéããäžèšã®äœçšå¹æãéæã§ã
ãã®ã¯ããã¯ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâ
ãã·ãªãžãåã³ãã®ççé©åæ§ã®é žæ·»å å¡©ã ãã§
ããããã®ç°æ§äœã§ããããã¯ãªãžã³âïŒâã«ã«
ãã³é žã®ïŒã»ïŒâãã·ãªãžãã¯ç¥çµæ¯ãæããã
ãã§ãªããæå¹ãªäžæŽèæ²»çå¹æã«æ¬ ããããã®
ããšã¯ååç©ãå³ã¡ããã©ã³ã¹ç¹èš±ç¬¬1566045
å·ã®è£œæ³ã§ãæ¬çºæã®è£œæ³ã§ã調補ãããããã¯
ãªãžã³âïŒâã«ã«ãã³é žã®ïŒã»ïŒâãã·ãªãžãå¡©
é žå¡©ã«é¢ããè©Šéšã«ãã€ãŠç«èšŒããããååç©
ãã¢ã«ããããŠã¹ã«è ¹è å æäžããçµæãäžèšã®
çç¶ãçŸããããæ äž é äœ çš å¹ æ 20â30mgïŒKg è奮ã移æéåãå¢å€§ 40â60mgïŒKg ç¥çµäžæ¯ãéå倱調ãéšåéº»çº 100mgïŒKg èŽæ»éãæ»å ã¯åŒåžå°é£ãšèŠãã
ãã è¬å€ã«ããèªçºããäžæŽèã«å¯Ÿããååç©ã®äœ
çšå¹æ ããããããã³ãã¿ãŒã«ã§éº»é ããŠãã2.7Kg
ã®ç«ã«ïŒæéã«äºãåèš70ÎŒïœïŒKgã®ãŠã¢ãã€ã³
ããã€ããæ³šå ¥ããããšã«ãã€ãŠäžæŽèãçºçã
ããããã®æ®µéã§å¿é»å³ã¯äž»ãšããŠå¿å®€æ§æ©ææ
åïŒæå€åçž®ïŒåã³å¿å®€é »èã«ããäžæŽèã®æã
ããªå åã瀺ãããååç©ã1.1mgïŒKgã®å²å
ã§éè泚å°ãããšããã现åãèµ·ãããæ»ã«è³ã€
ãã å ç¶åèéå¡ã«ããèªçºããäžæŽèã«å¯Ÿããåå
ç©ã®äœçšå¹æ 000çªçµ¹ç³žã§å·Šåäžè¡å ç¶åèãçµçŽ®ããããš
ã«ããäœé15Kgã®ç¬ã«äžæŽèãçºçããããæè¡
ã®24æéåŸãäžæŽèãäž»ãšããŠå¿å®€æ§é »èã®æã
ããªå åãå¿é»å³ã«çŸããããïŒmgïŒKgã®å²åã§
ååç©ãéè泚å°ããããå¿é»å³ã«çæéå ã
ã«æ¹åã®å åãçŸãããã«éããªãã€ãããã®å
é¢ãç°åžžãªè奮ãéŠã暪ã«æ¯ããªã©ã®ç¥çµäžæ¯ç
ç¶ãã¯ã€ãã芳å¯ãããã 以äžã®çµæã«ç §ãããŠååç©ãæäžæŽèå€ãš
ããŠäœ¿çšã§ããªãããšã¯æçœã§ããã 以äžæ¬çºæã®è£œæ³ãç¹ã«ååç©åã³ã®èª¿è£œ
ã«é¢é£ããŠèª¬æããããäžè¬çã«ã¯åŒ ã§è¡šããããããã¯ãªãžã³ã«ã«ãã³é žãç¡æ°Žã¯ã
ããã«ã äžã§å¡©åãªããµãªã«ã®ååšã«æŒããŠåŒ ã§è¡šããããã¢ããªã³ãšåå¿ãããããšã«ãã察
å¿ã®ããã¯ãªãžã³ã«ã«ãã³é žãã·ãªãžããçæã
ãããããååããããšãç¹åŸŽãšããäžèšååç©
ãåã³ããã«é¡äŒŒã®ååç©ã®è£œæ³ã§ããããš
ã¯äºããŸã§ããªããå°äžèšåŒäžã®R1åã³R2ã¯å
ã«è¿°ã¹ãã®ãšåæ§ã®å 容ãè¡šãããã®ãšããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ R1åã³R2ãæ°ŽçŽ ãããã²ã³åã³äœçŽã¢ã«ã
ã«ããæã矀ããéžã°ãããšããŠãåŒ ã§è¡šããããååç©ã®è£œæ³ã§ãã€ãŠãåŒ ã§è¡šããããããã¯ãªãžã³ã«ã«ãã³é žãç¡æ°Žã¯ã
ããã«ã äžã§äžã€å¡©åãªããµãªã«ã®ååšã«æŒã
ãŠãR1åã³R2ãäžèšãšåãæå³ãæã€ãšããŠåŒ ã§è¡šããããã¢ããªã³ãšåå¿ããã圢æãããå
èšããã¯ãªãžã³ã«ã«ãã³é žã®ã¢ããªã³èªå°äœãå
åããããšãç¹åŸŽãšããããã¯ãªãžã³ã«ã«ãã³é ž
èªå°äœã®è£œæ³ã ïŒ åå¿ç©ãéæµãããããšã«ãã€ãŠåèšåå¿ã
è¡ãªãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®è£œæ³ã ïŒ åèšããã¯ãªãžã³ã«ã«ãã³é žãããã¯ãªãžã³
âïŒâã«ã«ãã³é žåã³ããã¯ãªãžã³âïŒâã«ã«ã
ã³é žããæã矀ããéžæãããåèšã¢ããªã³ã
ïŒã»ïŒâãžã¡ãã«ã¢ããªã³ã§ããç¹èš±è«æ±ã®ç¯å²
第ïŒé ã«èšèŒã®è£œæ³ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL51296A IL51296A (en) | 1977-01-19 | 1977-01-19 | Antiarrhythmic composition comprising a quinuclidine-3-carboxylic acid anilide and novel method for the preparation of such anilides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53109952A JPS53109952A (en) | 1978-09-26 |
| JPS638111B2 true JPS638111B2 (ja) | 1988-02-19 |
Family
ID=11049358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP476478A Granted JPS53109952A (en) | 1977-01-19 | 1978-01-19 | Production of quinoqulisine carboxylic acid xylyside having antiiarrhythmia action |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS53109952A (ja) |
| AT (1) | AT355586B (ja) |
| AU (1) | AU519089B2 (ja) |
| CA (1) | CA1107734A (ja) |
| DE (1) | DE2802208A1 (ja) |
| DK (1) | DK147180C (ja) |
| ES (1) | ES465827A1 (ja) |
| FI (1) | FI773923A7 (ja) |
| FR (1) | FR2384499A1 (ja) |
| GB (2) | GB1578421A (ja) |
| IL (1) | IL51296A (ja) |
| NO (1) | NO148335C (ja) |
| NZ (1) | NZ185904A (ja) |
| PT (1) | PT67401B (ja) |
| SE (1) | SE443786B (ja) |
| ZA (1) | ZA777476B (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und PropionsÀureamide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE331841B (ja) * | 1967-05-23 | 1971-01-18 | Astra Ab |
-
1977
- 1977-01-19 IL IL51296A patent/IL51296A/xx unknown
- 1977-12-08 NZ NZ185904A patent/NZ185904A/en unknown
- 1977-12-14 PT PT67401A patent/PT67401B/pt unknown
- 1977-12-15 ZA ZA00777476A patent/ZA777476B/xx unknown
- 1977-12-23 FI FI773923A patent/FI773923A7/fi not_active Application Discontinuation
-
1978
- 1978-01-07 ES ES465827A patent/ES465827A1/es not_active Expired
- 1978-01-09 SE SE7800204A patent/SE443786B/sv unknown
- 1978-01-17 AU AU32489/78A patent/AU519089B2/en not_active Expired
- 1978-01-18 FR FR7801354A patent/FR2384499A1/fr active Granted
- 1978-01-18 DK DK26478A patent/DK147180C/da active
- 1978-01-18 NO NO780177A patent/NO148335C/no unknown
- 1978-01-18 AT AT35378A patent/AT355586B/de not_active IP Right Cessation
- 1978-01-18 CA CA295,163A patent/CA1107734A/en not_active Expired
- 1978-01-19 JP JP476478A patent/JPS53109952A/ja active Granted
- 1978-01-19 GB GB2197/78A patent/GB1578421A/en not_active Expired
- 1978-01-19 GB GB21014/79A patent/GB1578422A/en not_active Expired
- 1978-01-19 DE DE19782802208 patent/DE2802208A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ZA777476B (en) | 1978-10-25 |
| PT67401A (en) | 1978-01-01 |
| DK147180C (da) | 1984-11-12 |
| AU3248978A (en) | 1979-07-26 |
| GB1578422A (en) | 1980-11-05 |
| PT67401B (en) | 1979-05-21 |
| JPS53109952A (en) | 1978-09-26 |
| FI773923A7 (fi) | 1978-07-20 |
| FR2384499B1 (ja) | 1981-10-30 |
| ES465827A1 (es) | 1979-01-01 |
| CA1107734A (en) | 1981-08-25 |
| DK26478A (da) | 1978-07-20 |
| DE2802208A1 (de) | 1978-07-20 |
| AU519089B2 (en) | 1981-11-05 |
| DK147180B (da) | 1984-05-07 |
| NO148335B (no) | 1983-06-13 |
| SE443786B (sv) | 1986-03-10 |
| FR2384499A1 (fr) | 1978-10-20 |
| IL51296A (en) | 1983-10-31 |
| GB1578421A (en) | 1980-11-05 |
| NO780177L (no) | 1978-07-20 |
| ATA35378A (de) | 1979-08-15 |
| NZ185904A (en) | 1984-05-31 |
| IL51296A0 (en) | 1977-03-31 |
| AT355586B (de) | 1980-03-10 |
| NO148335C (no) | 1983-09-21 |
| SE7800204L (sv) | 1978-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3658966A (en) | Methods of treating hypertension | |
| TW202246206A (zh) | äžçš®æ²ååç°çŽ è¡çç©åå ¶çšé | |
| US7872137B2 (en) | Process for the preparation of mivacurium chloride | |
| CA2133324C (en) | Parenteral solutions containing 3-dialkylaminoethoxybenzoyl-benzofurans | |
| WO1999016431A1 (en) | Mixtures of enantiomers of aminocyclohexylamides to produce simultaneous analgesia with local anaesthesia or antiarrhythmia | |
| DE69109721T2 (de) | Pharmazeutische Zubereitung mit Wirkung auf das HerzgefÀsssystem, die 3-Methylthiopropionyl L-Carnitin enthÀlt. | |
| JPS638111B2 (ja) | ||
| EP4685128A1 (en) | Novel 2-(1-hydroxypentyl) benzoic acid cycloalkyl amine salt | |
| CN112294809B (zh) | äžç§äœæ¯æ§å±éšéº»éè¯åå ¶å¶å€æ¹æ³ | |
| US4146628A (en) | Antiarrhythmic quinuclidine carboxylic acid xylidide and method of producing the same and similar compounds | |
| AU568704B2 (en) | Ether of n-propanolamine derivative | |
| US4524152A (en) | 1-Cyano-3-(fluoroalkyl)guanidines for lowering blood pressure | |
| US4218477A (en) | Primary aminoacylanilides, methods of making the same and use as antiarrhythmic drugs | |
| KR102675526B1 (ko) | ëªšë žë©íž ížë§ë ìŽíž ì 구첎 ìœë¬Œ íí©ë¬Œ ë° ìŽë€ì ìœíì ì¡°ì±ë¬Œ | |
| JPS60116678A (ja) | ïœâãããããŒã«ã¢ãã³èªå°äœãšãŒãã« | |
| US4888359A (en) | Analgesic and antiinflammatory pharmaceutical composition containing a naphthyl-acetic acid derivative | |
| KR20050110681A (ko) | 2-(ë¶íž-1-ì€í¬ëìë¯žë ž)-ïœ-[1(ïœ)-(6-ë©í¡ìíŒëŠ¬ë-3-ìŒ)-íë¡í]-ë²€ìŠì믞ë, ìœë¬Œë¡ìì ìŽì ì©ë, ë° ìŽë¥Œíšì íë ìœì íì ì ì | |
| JPH0374233B2 (ja) | ||
| KR20210046115A (ko) | ëìì ì ë첎 ë° ìŽë¥Œ íšì íë ìœí ì¡°ì±ë¬Œ | |
| JPS62234029A (ja) | äžæ¢ç¥çµè³ŠæŽ»å€ | |
| DE2014201C3 (de) | Hydrochlorid des 10-(beta-morpholinopropionyl)-phenothiazin-2-carbamin-saeureaethylesters, verfahren zu dessen herstellung und pharmazeutisches mittel | |
| EP0786254A1 (en) | Preventive or remedy for kidney diseases | |
| Oppenheimer et al. | A Preclinical Study ofEO-122, a New Lidocaine-Like Antiarrhythmic Drug | |
| JPS6353989B2 (ja) | ||
| JPH0374673B2 (ja) |